Short interest for Surmodics gives investors a sense of the degree to which investors are betting on the decline of Surmodics's stock. Short interest data is updated every two weeks.

Surmodics Stock (NASDAQ:SRDX), Short Interest Report

Surmodics

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

amd shutter

News

Intraday Update

Markets

Movers

AKAN

ASTE

ATEN

CDNA

CETX

CHEF

CNDT

CTMX

CVRX

DBRG

DPSI

GETR

GRMN

IMCC

LGHL

LMND

MNDR

NARI

NCLH

NYCB

PALI

PINS

PLTN

POAI

POWL

PSNY

RCKY

ROOT

SBUX

SITE

SMCI

SOBR

SRDX

STGW

SWKS

TECH

TGTX

TMDX

UFPT

XTIA

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Image 4

AMCR

AXTA

DOCN

LIVN

UTHR

Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday

Penny Stocks

Small Cap

Trading Ideas

ALGM

ASST

BFRG

BOOT

BRTX

CACC

CELU

CHRW

CMAX

CMND

CMPR

CTVA

DGII

EGHT

ELAB

ELWS

ETSY

EVAX

EVER

FBLG

FCEL

HSAI

IFBD

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MINM

NRBO

NVIV

OGEN

PLUG

PTON

RACE

REVB

RKLB

SPWR

TCRT

VLCN

WOLF

YOSH

ZION

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Surmodics Inc

Needham analyst Mike Matson maintains Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Buy and lowers the price target from $47 to $43.

Price Target

Analyst Ratings

Needham Maintains Buy on Surmodics, Lowers Price Target to $43

Shares of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue <a href="https://www.benzinga.com/news/earnings/24/04/38534910/amd-investors-pull-back-after-modest-q1-beat-ceo-touts-ai-chip-ramp-up">guidance for the second quarter</a>.
AMD guided to second-quarter revenue of $5.7 billion plus or minus $300 million and a non-GAAP gross margin of about 53% against Street estimates of $5.7 billion in second-quarter revenue. Street expectations for fiscal year 2024 are for earnings of $3.40 per share and revenue of $24.13 billion, respectively, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Advanced Micro Devices shares dipped 6.9% to $147.44 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares jumped 97.5% to $3.2199. CytomX Therapeutics will report first quarter 2024 results and issue an initial CX-904 Phase 1a clinical data update on May 8.</li>
<li>IM Cannabis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) gained 41.3% to $1.2150 after jumping around 54% on Tuesday.</li>
<li>Akanda Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) gained 39.5% to $0.1295. Shares of cannabis-related stocks traded higher following reports suggesting the DEA plans to reclassify cannabis as a less dangerous drug.</li>
<li>Getaround, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETR#NYSE">GETR</a>) rose 35% to $0.2741 after the company announced it secured up to $50 million in additional financing.</li>
<li>Rocky Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) gained 31.6% to $33.93 after the company reported better-than-expected quarterly financial results.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 28% to $7.72 after the company announced completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-α production in a whole blood assay.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares rose 28% to $120.26 after the company raised its 2024 guidance.</li>
<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) gained 27.2% to $32.69 following strong quarterly results.</li>
<li>DecisionPoint Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPSI#NASDAQ">DPSI</a>) rose 24.6% to $10.03 as the company agreed to go private in all-cash transaction.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) rose 23.4% to $9.59. CareDx is expected to report financial results for the first quarter 2024 after the closing bell on Thursday, May 9.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) jumped 23.2% to $176.16 after the company reported better-than-expected second-quarter financial results.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) rose 21.7% to $16.64 following a first-quarter revenue beat and increased 2024 Briumvi US net product revenue outlook.</li>
<li>New York Community Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) climbed 20% to $3.1887 following quarterly results.</li>
<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) jumped 20.1% to $75.89 following upbeat quarterly results.</li>
<li>Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) shares gained 19.1% to $44.47 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 18% to $8.87.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) gained 17.7% to $15.38 following better-than-expected quarterly results.</li>
<li>Pinterest, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) rose 17.5% to $39.29 following strong first-quarter earnings and upbeat second-quarter guidance.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) shares climbed 17.2% to $81.66 after the company reported better-than-expected first-quarter financial results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.2% to $8.82 following upbeat earnings.</li>
<li>UFP Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) jumped 13.8% to $234.34 following upbeat earnings.</li>
<li>Conduent Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) rose 13.7% to $3.58 after the company reported better-than-expected first-quarter results and issued strong FY24 guidance.</li>
<li>Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) gained 13.1% to $6.73 following upbeat earnings.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) climbed 11.5% to $36.89 following strong quarterly earnings.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) rose 11% to $160.40 after the company reported better-than-expected first-quarter financial results and affirmed FY24 adjusted EPS and sales guidance, which is above estimates.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) rose 9.9% to $1.5699 after the company announced a collaboration with FluGen for an intranasal flu vaccine.</li>
<li>Trinity Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) gained 9.4% to $28.48 following upbeat earnings.</li>
<li>Plutonian Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTN#NASDAQ">PLTN</a>) gained 6.8% to $9.48.</li>
<li>Lion Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGHL#NASDAQ">LGHL</a>) shares gained 6.5% to $0.5188 after the company reported a year-over-year increase in FY23 financial results.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares gained 6% to $18.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 73.1% to $0.3054 after the company announced pricing of a $10 million upsized underwritten public offering.</li>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) dipped 61.8% to $9.41.</li>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 40.2% to $9.27 after the company reported worse-than-expected first-quarter financial results. JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and lowered the price target from $36 to $13.</li>
<li>Leggett &amp; Platt, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) fell 29.1% to $12.81 after the company reported worse-than-expected first-quarter financial results. The company also reduced its dividend.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) dipped 28.8% to $0.6052.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) fell 25.5% to $1.90</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) dipped 25% to $11.16.</li>
<li>Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) declined 22.3% to $0.1883.</li>
<li>Astec Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTE#NASDAQ">ASTE</a>) fell 21.1% to $32.99 following downbeat quarterly results.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) dipped 19.4% to $54.55 following worse-than-expected first-quarter EPS and revenues.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares declined 15.9% to $721.99 following mixed third-quarter financial results.</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) fell 15.8% to $74.54 following weaker-than-expected second-quarter earnings.</li>
<li>Ryerson Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYI#NYSE">RYI</a>) declined 15.1% to $24.25 after posting a loss for the first quarter.</li>
<li>DigitalBridge Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NASDAQ">DBRG</a>) fell 14.4% to $14.08 after the company reported first-quarter financial results.</li>
<li>Hillenbrand, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) dipped 14% to $41.04 after the company reported mixed second-quarter financial results and cut FY24 adjusted EPS guidance below estimates.</li>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares fell 13.7% to $92.01 after the company reported second-quarter financial results and issued third-quarter revenue guidance with the midpoint below estimates.</li>
<li>Sobr Safe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares declined 12.2% to $0.2801.</li>
<li>SiteOne Landscape Supply, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NASDAQ">SITE</a>) fell 11.6% to $138.66 after the company reported mixed first-quarter financial results.</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) fell 11% to $16.84 following a first-quarter revenue miss and soft FY24 guidance.</li>
<li>O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) fell 10.5% to $13.38 after the company reported worse-than-expected first-quarter sales results and cut FY24 adjusted EPS guidance.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) fell 9.7% to $132.39 after the company reported third-quarter financial results and issued FY24 adjusted EPS guidance below estimates.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) fell 9% to $111.68 after the company reported first-quarter financial results and issued guidance.</li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) dipped 8.8% to $66.59. A report earlier today indicated federal prosecutors are examining the company&#8217;s financial transactions.</li>
<li>The Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) fell 8.2% to $41.10 after the company reported first-quarter financial results.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares declined 7.9% to $1.2801. Polestar delayed annual report due to accounting errors.</li>
<li>The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) fell 6.3% to $36.19 following mixed first-quarter results.</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) fell 6% to $139.09 after the company reported worse-than-expected third-quarter sales results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38550761/how-to-earn-500-a-month-from-intel-stock-following-q1-earnings-report">How To Earn $500 A Month From Intel Stock Following Q1 Earnings Report</a>

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 154.6% to $4.15 during Wednesday's regular session. The market value of their outstanding shares is at $281.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 36.79% to $2.9. The market value of their outstanding shares is at $3.8 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 33.87% to $0.12. The company's market cap stands at $1.4 million. </li>
<li>Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) shares increased by 30.14% to $33.44. The market value of their outstanding shares is at $475.9 million. As per the news, the Q2 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 27.81% to $1.15. The market value of their outstanding shares is at $15.3 million. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares rose 27.75% to $120.26. The company's market cap stands at $3.9 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 36.9% to $9.79 during Wednesday's regular session. The market value of their outstanding shares is at $211.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares declined by 19.65% to $1.98. The market value of their outstanding shares is at $1.5 billion. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock fell 19.11% to $0.89. The company's market cap stands at $2.7 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock decreased by 18.38% to $0.39. The company's market cap stands at $21.5 million. </li>
<li>CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) stock fell 16.94% to $56.24. The market value of their outstanding shares is at $70.8 billion. The company's, Q1 earnings came out today. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock declined by 15.5% to $20.83. The company's market cap stands at $708.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCC

PHGE

TLRY

YCBD

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Surmodics shares are trading higher following a Q2 earnings beat.

U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday.
Shares of Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/POWL/earnings">second-quarter financial results</a>.
Powell Industries posted GAAP earnings of $2.75 per share, beating market estimates of $1.77 per share. The company's quarterly sales came in at $255.108 million versus expectations of $201.447 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Powell Industries shares jumped 23.2% to $176.16 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Rocky Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) shares jumped 31.6% to $33.93 after the company reported better-than-expected quarterly financial results.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares climbed 28% to $120.26 after the company raised its 2024 guidance.</li>
<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) rose 27.2% to $32.69 following strong quarterly results.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares gained 23.4% to $9.59. CareDx is expected to report financial results for the first quarter 2024 after the closing bell on Thursday, May 9.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) rose 21.7% to $16.64 following a first-quarter revenue beat and increased 2024 Briumvi US net product revenue outlook.</li>
<li>New York Community Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) jumped 20% to $3.1887 following quarterly results.</li>
<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) rose 20.1% to $75.89 following upbeat quarterly results.</li>
<li>Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) shares gained 19.1% to $44.47 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) surged 18% to $8.87.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) climbed 17.7% to $15.38 following better-than-expected quarterly results.</li>
<li>Pinterest, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) gained 17.5% to $39.29 following strong first-quarter earnings and upbeat second-quarter guidance.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) shares gained 17.2% to $81.66 after the company reported better-than-expected first-quarter financial results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) rose 17.2% to $8.82 following upbeat earnings.</li>
<li>UFP Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) gained 13.8% to $234.34 following upbeat earnings.</li>
<li>Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) rose 13.1% to $6.73 following upbeat earnings.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) gained 11.5% to $36.89 following strong quarterly earnings.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) climbed 11% to $160.40 after the company reported better-than-expected first-quarter financial results and affirmed FY24 adjusted EPS and sales guidance, which is above estimates.</li>
<li>Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) gained 10% to $9.84 after the company reported mixed third-quarter financial results and updated guidance.</li>
<li>Trinity Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) rose 9.4% to $28.48 following upbeat earnings.</li>
<li>Axos Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) surged 9.3% to $55.31 following better-than-expected earnings.</li>
<li>Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) gained 9.2% to $34.32 following better-than-expected quarterly results.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) climbed 8.1% to $92.61 on strong quarterly earnings.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) rose 8.1% to $78.39 as the company reported a first-quarter fiscal 2024 sales decline of 3% year-over-year to $2.931 billion, beating the consensus of $2.813 billion.</li>
<li>Clean Harbors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) gained 8% to $204.59 after the company reported better-than-expected quarterly financial results.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) gained 7.7% to $35.38 after it was announced the stock will join the S&amp;P SmallCap 600.</li>
<li>LivaNova PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) gained 7.4% to $59.86 after the company posted upbeat quarterly earnings and raised FY24 forecast.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) gained 6.2% to $248.95 after the company reported better-than-expected quarterly financial results.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares rose 6% to $18.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38549444/exxon-mobil-kimberly-clark-and-2-other-stocks-insiders-are-selling">Exxon Mobil, Kimberly-Clark And 2 Other Stocks Insiders Are Selling</a>

Guidance

Surmodics Sees FY24 Adj. EPS $(0.64)-$(0.47) Vs $(0.94) Est.; Revenue $122M-$124M Vs $119.644M Est.

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.32) by 121.88 percent. The company reported quarterly sales of $31.958 million which beat the analyst consensus estimate of $28.844 million by 10.80 percent. This is a 17.50 percent increase over sales of $27.198 million the same period last year.

Earnings

Earnings Beats

Surmodics Q2 2024 Adj EPS $0.07 Beats $(0.32) Estimate, Sales $31.958M Beat $28.844M Estimate

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Buy and maintains $47 price target.

Reiteration

Needham Reiterates Buy on Surmodics, Maintains $47 Price Target

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrw#NASDAQ">CHRW</a>) fell sharply during Thursday&rsquo;s session after the company reported worse-than-expected fourth-quarter financial results.
C.H. Robinson Worldwide posted adjusted earnings of 50 cents per share, missing market estimates if 81 cents per share. The company&rsquo;s quarterly sales came in at $4.20 billion versus estimates of $4.34 billion.
C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares climbed 57.3% to $6.45. David E. Lazar recently disclosed a 51% active stake in Minim.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) jumped 51% to $2.17. Clearmind Medicine announced long-term licensing agreement with BIRAD.</li>
<li>NeuroBo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrbo#NASDAQ">NRBO</a>) climbed 52.9% to $5.00. NeuroBo Pharmaceuticals announced FDA clearance of IND for Phase 1 clinical trial of DA-1726 for the treatment of obesity.</li>
<li>FibroBiologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fblg#NASDAQ">FBLG</a>) shares climbed 47.4% to $42.90. FibroBiologics announced direct listing on the NASDAQ.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) rose 36% to $0.5191. Celularity said it sees FY24 net sales of $50 million to $56 million.</li>
<li>Cimpress plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmpr#NASDAQ">CMPR</a>) jumped 28.8% to $96.90 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares.</li>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) rose 28% to $0.2950.</li>
<li>Elevai Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elab#NASDAQ">ELAB</a>) gained 23.5% to $0.84 after gaining 8% on Wednesday.</li>
<li>Asset Entities Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asst#NASDAQ">ASST</a>) climbed 22.8% to $0.5650.</li>
<li>Kiora Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kprx#NASDAQ">KPRX</a>) shares jumped 20.4% to $0.6649. Kiora Pharmaceuticals announced a private placement of up to $45 million.</li>
<li>Evaxion Biotech A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evax#NASDAQ">EVAX</a>) gained 19.5% to $4.70. Evaxion Biotech announced pricing of $15 million public offering of 3.750 million ADS at $4.00 per ADS.</li>
<li>Nextracker Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxt#NASDAQ">NXT</a>) rose climbed 18.8% to $53.79 after the company reported better-than-expected third-quarter financial results.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) jumped 18.1% to $3.5791.</li>
<li>BioRestorative Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brtx#NASDAQ">BRTX</a>) gained 16.4% to $1.8850.</li>
<li>Corteva, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctva#NYSE">CTVA</a>) gained 16.2% to $52.84 after the company reported better-than-expected quarterly financial results, issued 2024 guidance and announced a $1 billion repurchase plan.</li>
<li>Nextracker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nxt#NYSE">NXT</a>) jumped 16.1% to $52.56 after the company reported better-than-expected quarterly financial results.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) rose 15.9% to $5.10.</li>
<li>FuelCell Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fcel#NASDAQ">FCEL</a>) gained 15.7% to $1.3885.</li>
<li>Plug Power Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plug#NASDAQ">PLUG</a>) climbed 12.2% to $4.9900. Plug Power said it completed first customer fill of liquid green hydrogen at its Georgia plant.</li>
<li>Credit Acceptance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cacc#NASDAQ">CACC</a>) jumped 11.9% to $605.43 following upbeat earnings.</li>
<li>Digi International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dgii#NASDAQ">DGII</a>) gained 11.7% to $27.17 following strong results.</li>
<li>Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) gained 11.1% to $2.5561 after dipping around 34% on Wednesday. Oragenics recently announced termination of at-market offering program.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/algm#NASDAQ">ALGM</a>) climbed 10.9% to $28.77 following upbeat earnings.</li>
<li>Ferrari N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/race#NYSE">RACE</a>) gained 10.4% to $382.17 after the company reported fourth-quarter financial results and issued 2024 guidance.</li>
<li>Etsy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) rose 9.6% to $72.95 after the company announced the appointment of Elliott Investment Management&rsquo;s Marc Steinberg to its board.</li>
<li>Boot Barn Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/boot#NYSE">BOOT</a>) gained 8.4% to $77.79 following upbeat earnings.</li>
<li>Sally Beauty Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbh#NYSE">SBH</a>) jumped 7.4% to $13.24 following upbeat earnings.</li>
<li>EverQuote, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ever#NASDAQ">EVER</a>) gained 7.2% to $13.53.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/db#NYSE">DB</a>) shares gained 6.2% to $13.65 after the company posted fourth-quarter results and announced plans to cut 3,500 jobs. Deutsche Bank plans to increase both share repurchases and dividends by at least 50% year-over-year in 2024.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/revb#NASDAQ">REVB</a>) shares dipped 61.1% to $3.4268 after the company announced pricing of $6.2 million public offering.</li>
<li>InVivo Therapeutics Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nviv#NASDAQ">NVIV</a>) fell 49% to $0.3267. InVivo Therapeutics Holdings and subsidiary filed for Chapter 11 bankruptcy in Delaware but plan to continue operating under court supervision as a debtor-in-possession.</li>
<li>Hesai Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsai#NASDAQ">HSAI</a>) declined 28.2% to $4.1817. Hesai Group issued a statement on the U.S. Department of Defense &quot;Chinese Military Companies&quot; list.</li>
<li>FibroBiologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fblg#NASDAQ">FBLG</a>) fell 27.4% to $21.12.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) shares dipped 24.3% to $0.1020 after the company announced a 1-for-45 reverse stock split.</li>
<li>Peloton Interactive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pton#NASDAQ">PTON</a>) fell 22.9% to $4.2850 after the company reported mixed second-quarter financial results and issued third-quarter revenue guidance below estimates.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) fell 21.4% to $8.10.</li>
<li>ADDvantage Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) shares declined 21.3% to $1.4320.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) fell 21.2% to $0.44 after surging more than 55% on Wednesday.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares declined 20.6% to $1.0799 after surging over 115% on Wednesday.</li>
<li>Alaunos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrt#NASDAQ">TCRT</a>) fell 19.3% to $2.0410.</li>
<li>Rocket Lab USA, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rklb#NASDAQ">RKLB</a>) shares declined 18.7% to $3.9450 after the company announced a proposed offering of $275 million convertible senior notes.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) fell 18.4% to $3.9736 after declining 9% on Wednesday. Bullfrog AI Holdings recently filed shelf offering of 786,938 shares and accompanying warrants at $6.63 per share and accompanying warrant.</li>
<li>Thermon Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/thr#NYSE">THR</a>) fell 16.2% to $27.45 following third-quarter results.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) declined 15.9% to $1.8250 after Volvo Cars said it will no longer provide further funding to the company.</li>
<li>Surmodics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srdx#NASDAQ">SRDX</a>) fell 14.9% to $29.97 following first-quarter results.</li>
<li>MaxLinear, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mxl#NYSE">MXL</a>) shares dipped 14.4% to $17.83 after reporting fourth-quarter results.</li>
<li>8x8, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eght#NASDAQ">EGHT</a>) fell 13.5% to $2.9050 following weak sales.</li>
<li>New York Community Bancorp, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NYSE">NYCB</a>) dipped 13.5% to $5.60 after multiple firms downgraded the stock following the company&#39;s fourth-quarter results.</li>
<li>IHS Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) fell 11.9% to $3.5050.</li>
<li>Western Alliance Bancorporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wal#NYSE">WAL</a>) dipped 10% to $57.58.</li>
<li>Aflac Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/afl#NYSE">AFL</a>) shares declined 9.7% to $76.17 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Markel Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkl#NYSE">MKL</a>) dipped 9.4% to $1,356.53 after the company reported 2023 financial results.</li>
<li>Wolfspeed, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wolf#NYSE">WOLF</a>) shares fell 9.2% to $29.56 following the company&#39;s second-quarter earnings.</li>
<li>Valley National Bancorp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vly#NASDAQ">VLY</a>) dipped 8% to $8.85.</li>
<li>Zions Bancorporation, National Association (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zion#NASDAQ">ZION</a>) fell 6.6% to $39.12.</li>
<li>ING Groep N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ing#NYSE">ING</a>) shares declined 5.9% to $13.37 following fourth-quarter results.</li>
<li>Sanofi (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sny#NASDAQ">SNY</a>) fell 3.2% to $48.33 after the company posted fourth-quarter results and named Fran&ccedil;ois-Xavier Roger as Chief Financial Officer.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/36889477/bitcoin-falls-following-jobless-claims-data-jupiter-ftx-token-among-top-losers"> Bitcoin Falls Following Jobless Claims Data; Jupiter, FTX Token Among Top Losers</a>

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Needham analyst Mike Matson maintains Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Buy and raises the price target from $44 to $47.

Needham Maintains Buy on Surmodics, Raises Price Target to $47

Surmodics shares are trading lower after the company reported Q1 financial results and issued FY23 guidance.

Health Care

General

Surmodics Expects FY24 Adjusted EPS Loss Of $(1.17)-$(0.87) Compared To The Prior Guidance Of $(1.32)-$(0.97) And Consensus Of $(1.16)

Surmodics Expects FY24 Sales Of $117M-$121M, And $113M-$117M, Excluding SurVeil DCB License Fee Revenue, Compared To The Prior Guidance Of $116M-$121M, And $112M-$117M, Respectively, And The Consensus Of $119.26M

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.30) by 100.33 percent. This is a 100.2 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $30.55 million which beat the analyst consensus estimate of $29.64 million by 3.08 percent. This is a 22.54 percent increase over sales of $24.93 million the same period last year.

Surmodics Q1 Adjusted EPS $0.00 May Not Be Comparable To $(0.30) Estimate, Sales $30.55M Beat $29.64M Estimate

AAPL

AMZN

ATKR

BALL

BrightSphere Investment Group plc Ordinary Shares

BSIG

CLFD

COLM

COUR

CSWI

CVCO

DECK

ENSG

EVBN

EXPO

FCFS

FLWS

GOOS

HOLX

HUBG

Janus Henderson Group plc Ordinary Shares

KMPR

LANC

LESL

LPLA

MATW

MCHP

MIXT

MTSI

OCSL

ONEW

OTEX

PFSI

POST

RVTY

SHEL

SILC

SIRI

SKYW

TEAM

TSCO

VIAV

Earnings Scheduled For February 1, 2024

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-01. Here's what investors need to know before the announcement.
Analysts estimate that Surmodics will report an earnings per share (EPS) of $-0.30. 
Surmodics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.35, which was followed by a 5.93% drop in the share price the next day.
Here's a look at Surmodics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.18</td>
<td>0.05</td>
<td>-0.48</td>
<td>-0.66</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.53</td>
<td>0.52</td>
<td>-0.40</td>
<td>-0.50</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.93%</td>
<td>0.09%</td>
<td>-3.88%</td>
<td>3.31%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1706727698_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Surmodics were trading at $34.96 as of January 30. Over the last 52-week period, shares are up 23.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SRDX/earnings">To track all earnings releases for Surmodics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Surmodics's Earnings

The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently in limited market evaluation (LME), with full commercial launch planned following completion of the LME.

Surmodics Announced Early Clinical Use Of The Company's Pounce LP (Low Profile) Thrombectomy System

Surmodics Announced 24-month Data From The Swing Trial, A First-in-human Study Of The Safety And Performance Of Sundance Sirolimus Drug-Coated Balloon (DCB) At 50th annual VEITH Symposium In New York

Surmodics Announced The presentation Of 36-month Data From Its Transcend Clinical Trial By Dr. Peter A. Schneider At The 50th Annual Veith Symposium In New York, New York

Barrington Research analyst Michael Petusky maintains Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Outperform and raises the price target from $69 to $71.

Barrington Research Maintains Outperform on Surmodics, Raises Price Target to $71

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SurModics (SRDX – Research Report) and Biogen (BIIB ...

Analysts Are Bullish on Top Healthcare Stocks: SurModics (SRDX), Biogen (BIIB)

Surmodics (SRDX) has released an update. Surmodics, Inc. shareholders convened on February 8, 2024, where they decisively elected all nominated Cla...

Surmodics Shareholders Approve Directors and Fiscal Oversight

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genprex (GNPX – Research Report) and SurModics (SRDX...

Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)

Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down

Surmodics beats top-line and bottom-line estimates; updates FY24 outlook

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SurModics (SRDX – Research Report) and Pfizer (PFE...

Analysts Offer Insights on Healthcare Companies: SurModics (SRDX) and Pfizer (PFE)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Surmodics (NASDAQ:<a href="https://investorplace.com/stock-quotes/srdx-stock-quote/">SRDX</a>) just reported results for the second quarter of 2024.<ul><li>Surmodics reported earnings per share of 7 cents. This was above the analyst estimate for EPS of -32 cents.</li><li>The company reported revenue of $31.96 million.</li><li>This was 10.81% better than the analyst estimate for revenue of $28.84 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/srdx-stock-earnings-surmodics-for-q2-of-2024/">SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Surmodics Stock (NASDAQ:SRDX), Short Interest Report

People Also Watch